December 18, 2013
SON, NetherlandsThe newest study from Rousselot confirmed Peptan® collagen's benefits for knee joint pain and function. Conducted in collaboration with the Shanghai 6th Peoples Hospital of Shanghai Jiaotong University in China, the double blind, placebo-controlled study analyzed the collagen's effects on osteoarthritis (OA).
For the study, 100 women between ages 40 and 70 with OA received either 8 g of Peptan collagen peptides (from Rousselot) or placebo daily for six months. Researchers assessed joint pain and function using the WOMAC and Lysholm tests before treatment, then at three and six months.
Patients receiving supplementation lowered WOMAC scores over time, compared to the placebo group. The collagen peptide group also scored higher on the Lysholm scale, which measure joint function during activities such as stair climbing, walking and jumping. Researchers found no side effects with supplementation. The company said the study results will be published in April 2014.
"As one of the major causes of disability in the developed world, osteoarthritis is a leading source of limited mobility and joint pain for both men and women and its prevalence is set to increase as the population ages," said Janne Prawitt, Ph.D., general nutrition manager at Rousselot, which recently won Frost & Sullivan's 2013 Global Product Line Strategy Award for the Peptan brand.
You May Also Like
Advancing gender equity in the nutraceutical industrySep 25, 2023
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023